Skip to main content
PMC home page
Gut logoLink to Gut
. 1985 Jan;26(1):14–19. doi: 10.1136/gut.26.1.14

Pharmacology of propranolol in patients with cirrhosis and portal hypertension.

M J Arthur, A R Tanner, C Patel, R Wright, A G Renwick, C F George
PMCID: PMC1432408  PMID: 3965362

Abstract

Ten patients with cirrhosis and protal hypertension received an initial 20 mg oral test dose of propranolol and subsequently 160 mg of a slow release preparation, orally, each day for seven days. Protein binding, serial plasma propranolol concentrations and effects on heart rate were studied. Protein binding was slightly reduced (mean 85%, range 78.9-88.1%) compared with four normals (mean 87.9%). In patients with severe liver disease (serum albumin less than 30 g/l) propranolol remained detectable in plasma 24 hours after the single 20 mg dose and high steady state concentrations (mean 266.5 ng/ml, range 84-406) were observed during regular dosing. At steady state there was a significant correlation between log total plasma propranolol concentrations and the percentage fall in heart rate (r = 0.659, p less than 0.05). We suggest that in patients with severe liver chronic disease (serum albumin less than 30 g/l), propranolol therapy should be initiated in hospital. The starting dose should be low (20 mg of the conventional formulation tds or 80 mg of the slow release preparation daily) and that regular monitoring of the heart rate should be carried out.

Full text

PDF
14

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Branch R. A., James J., Read A. E. A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. Br J Clin Pharmacol. 1976 Apr;3(2):243–249. doi: 10.1111/j.1365-2125.1976.tb00599.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Burroughs A. K., Jenkins W. J., Sherlock S., Dunk A., Walt R. P., Osuafor T. O., Mackie S., Dick R. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med. 1983 Dec 22;309(25):1539–1542. doi: 10.1056/NEJM198312223092502. [DOI] [PubMed] [Google Scholar]
  3. Evans G. H., Nies A. S., Shand D. G. The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther. 1973 Jul;186(1):114–122. [PubMed] [Google Scholar]
  4. Evans G. H., Shand D. G. Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):487–493. doi: 10.1002/cpt1973144part1487. [DOI] [PubMed] [Google Scholar]
  5. George C. F., Orme M. L., Buranapong P., Macerlean D., Breckenridge A. M., Dollery C. T. Contribution of the liver to overall elimination of propranolol. J Pharmacokinet Biopharm. 1976 Feb;4(1):17–27. doi: 10.1007/BF01271441. [DOI] [PubMed] [Google Scholar]
  6. Leahey W. J., Neill J. D., Varma M. P., Shanks R. G. Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol. 1980 Jan;9(1):33–40. doi: 10.1111/j.1365-2125.1980.tb04793.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lebrec D., Nouel O., Corbic M., Benhamou J. P. Propranolol--a medical treatment for portal hypertension? Lancet. 1980 Jul 26;2(8187):180–182. doi: 10.1016/s0140-6736(80)90063-x. [DOI] [PubMed] [Google Scholar]
  8. Lebrec D., Poynard T., Hillon P., Benhamou J. P. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med. 1981 Dec 3;305(23):1371–1374. doi: 10.1056/NEJM198112033052302. [DOI] [PubMed] [Google Scholar]
  9. McDevitt D. G., Frisk-Holmberg M., Hollifield J. W., Shand D. G. Plasma binding and the affinity of propranolol for a beta receptor in man. Clin Pharmacol Ther. 1976 Aug;20(2):152–157. doi: 10.1002/cpt1976202152. [DOI] [PubMed] [Google Scholar]
  10. Nation R. L., Peng G. W., Chiou W. L. High-pressure liquid chromatographic method for the simultaneous quantitative analysis of propranolol and 4-hydroxypropranolol in plasma. J Chromatogr. 1978 May 1;145(3):429–436. doi: 10.1016/s0378-4347(00)81372-9. [DOI] [PubMed] [Google Scholar]
  11. Piafsky K. M., Borgá O., Odar-Cederlöf I., Johansson C., Sjöqvist F. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med. 1978 Dec 28;299(26):1435–1439. doi: 10.1056/NEJM197812282992604. [DOI] [PubMed] [Google Scholar]
  12. Prichard B. N., Gillam P. M. Assessment of propranolol in angina pectoris. Clinical dose response curve and effect on electrocardiogram at rest and on exercise. Br Heart J. 1971 Jul;33(4):473–480. doi: 10.1136/hrt.33.4.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pugh R. N., Murray-Lyon I. M., Dawson J. L., Pietroni M. C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646–649. doi: 10.1002/bjs.1800600817. [DOI] [PubMed] [Google Scholar]
  14. Shand D. G., Rangno R. E. The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology. 1972;7(3):159–168. doi: 10.1159/000136285. [DOI] [PubMed] [Google Scholar]
  15. Tarver D., Walt R. P., Dunk A. A., Jenkins W. J., Sherlock S. Precipitation of hepatic encephalopathy by propranolol in cirrhosis. Br Med J (Clin Res Ed) 1983 Aug 27;287(6392):585–585. doi: 10.1136/bmj.287.6392.585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Waller D. G., Smith C. L., Renwick A. G., George C. F. Intravenous propranolol in patients with inflammation. Br J Clin Pharmacol. 1982 Apr;13(4):577–578. doi: 10.1111/j.1365-2125.1982.tb01426.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Woosley R. L., Kornhauser D., Smith R., Reele S., Higgins S. B., Nies A. S., Shand D. G., Oates J. A. Suppression of chronic ventricular arrhythmias with propranolol. Circulation. 1979 Oct;60(4):819–827. doi: 10.1161/01.cir.60.4.819. [DOI] [PubMed] [Google Scholar]
  18. Zeegen R., Drinkwater J. E., Dawson A. M. Method for measuring cerebral dysfunction in patients with liver disease. Br Med J. 1970 Jun 13;2(5710):633–636. doi: 10.1136/bmj.2.5710.633. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES